Although cancer stem cells (CSCs) present an appealing therapeutic target in oral squamous cells carcinomas (OSCCs), a consensus molecular profile for such oral CSCs has not emerged. CSC eradication is further hampered by growing evidence of phenotypic plasticity in some non-CSCs allowing them to return to the CSC pool. Accurately defining oral CSCs together with mechanisms for restoring them after targeted depletion would establish a novel conceptual framework for effective OSCC therapy. Our preliminary work has isolated a drug-resistant subset of slow-cycling JARID1B-hi cells as a candidate CSC population in OSCC. JARID1B, a histone demethylase whose expression identifies CSCs by functional criteria in other cancer types, shows promise as a generalizable CSC marker based on its ability to mediate entry into a stem cell-like epigenetic state. Hyper-activation of the PI3-kinase (PI3K) pathway in JARID1B-hi cells renders them sensitive to depletion by PI3K-targeted drugs. Our working hypothesis is that a depleted JARID1B-hi CSC pool can be replenished by a population of quiescent """"""""G0-like"""""""" cells, which have both high growth potential and drug resistance. While lacking the stem cell markers and PI3K pathway activity seen in JARID1B-hi cells, G0-like cells do show prominent Notch pathway activation, which has been linked to CSC population expansion and increased PI3K/AKT signaling. To explain these findings, our overall hypothesis is that entry of proliferative OSCC cells into a quiescent, G0-like state creates a reservoir to prevent permanent CSC depletion by providing a direct precursor to JARID1B-hi cells. To test this hypothesis, we will first test the roles of JARID1B- hi and G0-like subsets in OSCC growth using conventional CSC criteria (aim 1). We will specifically test whether JARID1B-hi cells have independent CSC functions, while tumor formation by G0-like cells may depend upon the JARID1B-hi fraction. Additional studies will define the precise role of G0-like cells in sustaining the JARID1B-hi population in OSCC (aim 2). Here we test whether Notch-mediated entry of non-CSCs into a quiescent G0-like state forms a direct precursor for JARID1B-hi cells, thus providing a reservoir for CSC repopulation. Validation of these concepts here would establish new model systems to dissect mechanisms underlying the cell state transitions that prevent durable oral CSC depletion during treatment. In doing so, our work will also facilitate translational studies to jointly target two distinct tumor cell phenotypes that cooperatively sustain OSCC growth via the Notch and PI3K pathways.

Public Health Relevance

OSCC is a major public health issue in the US, accounting for approximately 36,000 annual cases and 8000 deaths as well as severe treatment-related disabilities in many survivors. Our preliminary data support that G0- like cells are a treatment-resistant reservoir that prevents lasting depletion of the CSCs sustaining OSCC growth. This proposal therefore pursues mechanisms by which G0-like cells support the CSC pool in order to provide basis for targeting the G0-like cell state and ultimately improving outcomes for OSCC patients. PROJECT NARRATIVE Accurately defining oral cancer stem cells together with mechanisms for restoring them after their depletion would establish a novel conceptual framework for effective oral cancer therapy. Here we pursue the hypothesis is that depleted oral cancer stem cells can be replenished by a population of quiescent G0-like cells, which have both high growth potential and drug resistance. Validation of this concept would provide basis for addressing the cell state transitions that prevent oral cancer stem cell eradication during treatment.

National Institute of Health (NIH)
National Institute of Dental & Craniofacial Research (NIDCR)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZDE1-RK (24))
Program Officer
Venkatachalam, Sundaresan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998
Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970
Facompre, Nicole D; Harmeyer, Kayla H; Basu, Devraj (2017) Regulation of oncogenic PI3-kinase signaling by JARID1B. Oncotarget 8:7218-7219
Natsuizaka, Mitsuteru; Whelan, Kelly A; Kagawa, Shingo et al. (2017) Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. Nat Commun 8:1758
Facompre, Nicole D; Sahu, Varun; Montone, Kathleen T et al. (2017) Barriers to generating PDX models of HPV-related head and neck cancer. Laryngoscope 127:2777-2783
Harmeyer, Kayla M; Facompre, Nicole D; Herlyn, Meenhard et al. (2017) JARID1 Histone Demethylases: Emerging Targets in Cancer. Trends Cancer 3:713-725
Zhang, Gao; Frederick, Dennie T; Wu, Lawrence et al. (2016) Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126:1834-56
Facompre, Nicole D; Harmeyer, Kayla M; Sole, Xavier et al. (2016) JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Res 76:5538-49
Kagawa, S; Natsuizaka, M; Whelan, K A et al. (2015) Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene 34:2347-59